Apleway

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异香豆素
• 英文名称: Apleway
• 英文别名: 5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol
• 化学式: C₂₂H₂₆O₆
• 分子量: 386.4
• InChiKey: VWVKUNOPTJGDOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• NOVEL COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE
  申请人：UNIVERSITE PARIS DESCARTES

  公开号：US20200030297A1

  公开（公告）日：2020-01-30

  The invention relates to a compound inhibiting the interaction between a Grb14 protein and an insulin receptor of Formula (I) or Formula (II), their salts, solvates, and/or diastereoisomers, for use for therapeutic purposes, in particular for the treatment of insulin resistance, and to pharmaceutical compositions containing such compounds.

  该发明涉及一种抑制Grb14蛋白与化学式（I）或化学式（II）的胰岛素受体之间相互作用的化合物，其盐、溶剂合物和/或对映异构体，用于治疗目的，特别是用于治疗胰岛素抵抗，并且涉及含有这种化合物的药物组合物。
• Compounds, compositions and methods for treating insulin resistance
  申请人：UNIVERSITE PARIS DESCARTES

  公开号：US11020378B2

  公开（公告）日：2021-06-01

  The invention relates to a compound inhibiting the interaction between a Grb14 protein and an insulin receptor of Formula (I) or Formula (II), their salts, solvates, and/or diastereoisomers, for use for therapeutic purposes, in particular for the treatment of insulin resistance, and to pharmaceutical compositions containing such compounds.

  本发明涉及一种抑制 Grb14 蛋白与式（I）或式（II）胰岛素受体之间相互作用的化合物、 它们的盐、溶解物和/或非对映异构体，用于治疗目的，特别是治疗胰岛素抵抗，以及含有此类化合物的药物组合物。
• NOUVEAUX COMPOSES, COMPOSITIONS ET METHODES POUR LE TRAITEMENT DE LA RESISTANCE A L'INSULINE
  申请人：Université Paris Diderot

  公开号：EP3600296A1

  公开（公告）日：2020-02-05
• [EN] NOVEL COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE<br/>[FR] NOUVEAUX COMPOSES, COMPOSITIONS ET METHODES POUR LE TRAITEMENT DE LA RESISTANCE A L'INSULINE
  申请人：UNIV PARIS DIDEROT

  公开号：WO2018172306A1

  公开（公告）日：2018-09-27

  L'invention porte sur un composé inhibiteur de l'interaction entre une protéine Grb14 et un récepteur de l'insuline de formule (I) ou de formule (II), leurs sels, solvates et/ou diastéréoisomères, pour une utilisation à des fins thérapeutiques, en particulier pour le traitement de l'insulinorésistance, et des compositions pharmaceutiques contenant de tels composés.
• [EN] SGLT2 INHIBITORS FOR THE TREATMENT OF NEUTROPENIA<br/>[FR] INHIBITEURS DE SGLT2 POUR LE TRAITEMENT DE LA NEUTROPÉNIE
  申请人：UNIV CATHOLIQUE LOUVAIN

  公开号：WO2019202149A1

  公开（公告）日：2019-10-24

  The present invention relates to the use of a SGLT2 (sodium glucose cotransporter 2) inhibitor for the treatment of neutropenia, in particular of neutropenia associated with an intracellular accumulation of 1,5-anhydroglucitol-6-phosphate. The present invention further relates to methods for determining whether a subject suffering from neutropenia is eligible for treatment with a SGLT2 inhibitor, for monitoring a neutropenia associated with an intracellular accumulation of 1,5-anhydroglucitol-6-phosphate and for monitoring the effectiveness of a treatment with a SGLT2 inhibitor.